Wang S, et al. – The intent behind this study, is to investigate the clinical and genetic features of Tuberous sclerosis complex (TSC) and to examine the treatment of facial angiofibromas, through topical sirolimus in Chinese children. Hypomelanotic macules serve as the first sign of TSC. Genetic testing exhibits a high detection rate in patients with a clinical diagnosis of TSC. Topical sirolimus is effective and well–tolerated as a treatment of facial angiofibromas. The response typically plateaus after 12 to 24 weeks of treatment.